DUN09716


Catalog No. size PriceQuantity
M6973-2 2mg solid $108
M6973-10 10mg solid $452

Description

Cas:300809-71-6

Product Information:

DUN09716 is KRAS inhibitor with potential antitumor activity. DUN09716 was reported inn patent US 9884046. DUN09716 has CAS# 300809-71-6, no formal name. For the convenience of scientific communication, we named it as DUN09716 (combined from Inchi key plus CAS#) according to Hodoodo Chemical Nomenclature

 

Chemical Formula: C13H9ClN2S2

 

Exact Mass: 291.9896

 

Molecular Weight: 292.799

 

Elemental Analysis: C, 53.33; H, 3.10; Cl, 12.11; N, 9.57; S, 21.90

 

Synonym:

 

DUN-09716

DUN 09716

 

Chemical Name:

4-[(Benzo[d]thiazol-2-yl)thio]-3-chloroaniline

 

InChi Key: 

DTSNLMOLTVGCGZ-UHFFFAOYSA-N

 

InChi Code: 

InChI=1S/C13H9ClN2S2/c14-9-7-8(15)5-6-11(9)17-13-16-10-3-1-2-4-12(10)18-13/h1-7H,15H2

 

Smiles Code:

NC1=CC=C(SC2=NC3=CC=CC=C3S2)C(Cl)=C1

 

 

Technical Data:

 

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

 

In Vitro:

KRAS inhibitor-9 bound to KRASG12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity of -5.38, -5.41, and -3.97 kcal/mol, respectively.

KRAS inhibitor-9 (0-100 μM) shows strong inhibition selectivity in NSCLC cells with IC50s ranging from 39.56 to 66.02 μM for H2122, H358 and H460 cells (at 72 hours).

KRAS inhibitor-9 (0-100 μM; 24 hours) blocks GTP-KRAS formation in H2122, H358 and H460 cells.

KRAS inhibitor-9 (25-100 μM; 48 hours) inhibits the activation of KRAS downstream signaling pathway.

KRAS inhibitor-9 (0-100 μM; 24-72 hours) induces cell cycle arrest and apoptosis in NSCLC.

 

 

References

 

  1. Xie C, et al. Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells. Front Pharmacol. 2017;8:823. Published 2017 Nov 14.

 

Products are for research use only. Not for human use.

Payment & Security

American Express Apple Pay Diners Club Discover Elo Google Pay JCB Mastercard PayPal Shop Pay Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed